Symbols

SNOA

Sonoma Pharmaceuticals·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 0

Ample Liquidity

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SNOA

Sonoma Pharmaceuticals, Inc.

A global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products

Industry

Healthcare Equipment and Supplies

Established Date

Listing Date

01/25/2007

Exchange

NASDAQ Stock Exchange

Full-time Employees

168

Fiscal Year Ends

03-31

Website

www.sonomapharma.com

Security Type

Common stock

Office address

5445 Conestoga Court, Suite 150, Boulder, Colorado 80301

Business

Introduction

Sonoma Pharmaceuticals, Inc., was incorporated under the laws of the State of California in April 1999 as Micromed Laboratories, Inc. In August 2001, the company changed its name to Oculus Innovative Sciences, Inc. In December 2006, the company was re-incorporated under Delaware law and is a global healthcare leader in the development and production of stable hypochlorous acid or HOCl products, which are widely used in wound care, animal health, eye care, oral health and dermatology.

Company Financials

EPS

SNOA has released its 2026 Q2 earnings. EPS was reported at -0.32, versus the expected -0.31, missing expectations. The chart below visualizes how SNOA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

SNOA has released its 2026 Q2 earnings report, with revenue of 5.60M, reflecting a YoY change of 56.58%, and net profit of -534.00K, showing a YoY change of 12.46%. The Sankey diagram below clearly presents SNOA's revenue sources and cost distribution.